Positioned as Leader in Emerging Psychedelic Therapeutics Market through Robust IP Portfolio, Novel Clinical Trials and Evolving Proprietary Technology Strengthened Balance Sheet with Approximately $30 Million in Capital Raised Subsequent to the Year-End Announced Appointment of Experienced Software and Engineering Leader, William Cook as Interim CEO of Mindleap DENVER, May 03, 2021 (GLOBE…


Previous articlePsychedelic Bulletin: MindMed Uplists to Nasdaq; Cybin Targets Alcoholism; COMPASS Announces $144m Offering
Next articleTryp Therapeutics Partners with Fluence for Psychotherapy Design